Genome
mining in association with the OSMAC (one strain, many compounds)
approach provides a feasible strategy to extend the chemical diversity
and novelty of natural products. In this study, we identified the
biosynthetic gene cluster (BGC) of restricticin, a promising antifungal
agent featuring a reactive primary amine, from the fungus Aspergillus sclerotiorum LZDX-33-4 by genome mining. Combining
heterologous expression and the OSMAC strategy resulted in the production
of a new hybrid product (1), along with N-acetyl-restricticin (2) and restricticinol (3). The structure of 1 was determined by spectroscopic
data, including optical rotation and electronic circular dichroism
(ECD) calculations, for configurational assignment. Compound 1 represents a fusion of restricticin and phytotoxic cichorin.
The biosynthetic pathway of 1 was proposed, in which
the condensation of a primary amine of restricticin with a precursor
of cichorine was postulated. Compound 1 at 5 mM concentration
inhibited the growth of the shoots and roots of Lolium perenne, Festuca arundinacea, and Lactuca sativa with inhibitory rates of 71.3 and 88.7% for L. perenne, 79.4 and 73.0% for F. arundinacea, and 58.2 and
52.9% for L. sativa. In addition, compound 1 at 25 μg/mL showed moderate antifungal activity against Fusarium fujikuroi and Trichoderma harzianum with inhibition rates of 22.6 and 31.6%, respectively. These results
suggest that heterologous expression in conjunction with the OSMAC
approach provides a promising strategy to extend the metabolite novelty
due to the incorporation of endogenous metabolites from the host strain
with exogenous compounds, leading to the production of more complex
compounds and the acquisition of new physiological functions.